Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in Netherton syndrome
NL-OMON59050Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of spesolimab in Netherton syndrome (NS) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: IASI response. Started Dec 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NL-OMON59050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59050.